These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31306399)

  • 1. Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.
    Danier J; Rivera L; Claeys C; Dbaibo G; Jain VK; Kosalaraksa P; Woo W; Yanni E; Zaman K; Acosta B; Amanullah A; Ariza M; Luisa Arroba Basanta M; Bavdekar A; Carmona A; Cousin L; Diaz A; Diez-Domingo J; Cagri Dinleyici E; Faust SN; Garcia-Sicilia J; Gomez-Go GD; Antionette Gonzales L; Hacimustafaoglu M; Hughes SM; Izu A; Jackowska T; Kant S; Lucero M; Mares Bermudez J; Martinón-Torres F; Montellano M; Prymula R; Puthanakit T; Ruzkova R; Sadowska-Krawczenko I; Soni J; Szymanski H; Ulied A; Schuind A; Innis BL;
    Pediatr Infect Dis J; 2019 Aug; 38(8):866-872. PubMed ID: 31306399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial.
    Dbaibo G; Amanullah A; Claeys C; Izu A; Jain VK; Kosalaraksa P; Rivera L; Soni J; Yanni E; Zaman K; Acosta B; Ariza M; Arroba Basanta ML; Bavdekar A; Carmona A; Cousin L; Danier J; Diaz A; Diez-Domingo J; Dinleyici EC; Faust SN; Garcia-Sicilia J; Gomez-Go GD; Gonzales MLA; Hacimustafaoglu M; Hughes SM; Jackowska T; Kant S; Lucero M; Mares Bermudez J; Martinón-Torres F; Montellano M; Prymula R; Puthanakit T; Ruzkova R; Sadowska-Krawczenko I; Szymanski H; Ulied A; Woo W; Schuind A; Innis BL;
    Pediatr Infect Dis J; 2020 Jan; 39(1):e1-e10. PubMed ID: 31725115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.
    Dunkle LM; Izikson R; Patriarca P; Goldenthal KL; Muse D; Callahan J; Cox MMJ;
    N Engl J Med; 2017 Jun; 376(25):2427-2436. PubMed ID: 28636855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres.
    Pepin S; Samson SI; Alvarez FP; Dupuy M; Gresset-Bourgeois V; De Bruijn I
    Vaccine; 2019 Mar; 37(13):1885-1888. PubMed ID: 30745147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.
    Claeys C; Chandrasekaran V; García-Sicilia J; Prymula R; Díez-Domingo J; Brzostek J; Marès-Bermúdez J; Martinón-Torres F; Pollard AJ; Růžková R; Carmona Martinez A; Ulied A; Miranda Valdivieso M; Faust SN; Snape MD; Friel D; Ollinger T; Soni J; Schuind A; Li P; Innis BL; Jain VK
    Pediatr Infect Dis J; 2019 Feb; 38(2):203-210. PubMed ID: 30325891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
    Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons.
    Claeys C; Zaman K; Dbaibo G; Li P; Izu A; Kosalaraksa P; Rivera L; Acosta B; Arroba Basanta ML; Aziz A; Cabanero MA; Chandrashekaran V; Corsaro B; Cousin L; Diaz A; Diez-Domingo J; Dinleyici EC; Faust SN; Friel D; Garcia-Sicilia J; Gomez-Go GD; Antoinette Gonzales ML; Hughes SM; Jackowska T; Kant S; Lucero M; Malvaux L; Mares Bermudez J; Martinon-Torres F; Miranda M; Montellano M; Peix Sambola MA; Prymula R; Puthanakit T; Ruzkova R; Sadowska-Krawczenko I; Salamanca de la Cueva I; Sokal E; Soni J; Szymanski H; Ulied A; Schuind A; Jain VK; Innis BL;
    Lancet Child Adolesc Health; 2018 May; 2(5):338-349. PubMed ID: 30169267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine for prevention of mild and moderate-to-severe influenza in children.
    Jain VK; Rivera L; Zaman K; Espos RA; Sirivichayakul C; Quiambao BP; Rivera-Medina DM; Kerdpanich P; Ceyhan M; Dinleyici EC; Cravioto A; Yunus M; Chanthavanich P; Limkittikul K; Kurugol Z; Alhan E; Caplanusi A; Durviaux S; Boutet P; Ofori-Anyinam O; Chandrasekaran V; Dbaibo G; Innis BL
    N Engl J Med; 2013 Dec; 369(26):2481-91. PubMed ID: 24328444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.
    Jain VK; Domachowske JB; Wang L; Ofori-Anyinam O; Rodríguez-Weber MA; Leonardi ML; Klein NP; Schlichter G; Jeanfreau R; Haney BL; Chu L; Harris JS; Sarpong KO; Micucio AC; Soni J; Chandrasekaran V; Li P; Innis BL
    J Pediatric Infect Dis Soc; 2017 Mar; 6(1):9-19. PubMed ID: 28062552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
    Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
    Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccines effectiveness 2013-14 through 2015-16, a test-negative study in children.
    Valdin HL; Bégué RE
    Vaccine; 2017 Jul; 35(33):4088-4093. PubMed ID: 28669621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.